1. Community Representative Update
Albert S. Makone

2. Introduction
Only people with drug-resistant TB (DR-TB) diagnosed (out of an estimated new DR TB cases),  and only 50% of those that started the life-saving DR-TB regimens are cured. 
WHO Global TB Report 2016

3. Key Activities
Enhance the understanding of Civil Society and key affected communities about the NDWG mandate
Share with Civil Society and key affected communities about the NDWG drug pipeline
Increasing NDWG membership
Distributing the call for membership in different regional networks
Building movement led by patients- including empowering and strengthening the voices of the affected community on TB research and new tools
Advocating to make TB services free and accessible
Participate in DR-TB STAT Taskforce to accelerate access to new drugs for MDR-TB

4. Key Issues
Engagement of TB affected communities at national, regional and global level remains superficial and limited.
The global battle to end TB will not be possible without the proper involvement of its most important stakeholder, the people and communities affected by this disease.

5. Moving Forward
Strengthen national and regional networks and coalitions of TB affected communities
Strengthen linkage with existing national, regional and global organizations and partners
To strengthen the capacity of TB affected community to be effectively engaged in all processes at all levels
To advocate for more resources and new tools for TB control

6. Moving Forward We need to do things differently!!!
Over 75% of TB money comes from Global Fund in Africa
Increase Domestic financing for health
Increase investment in TB R&D

7. Thank you
Tatenda
Ngiyabonga

8. 498DAYS #StepUpforTB DIAGNOSTICS No out-of-pocket costs
Rapid molecular tests
Second-line drug susceptibility tests 
MODELS OF CARE
PHC treatment, DRTB at district/below
Hospitalisation not required
Immediate ART for PLWHA
DRUG REGULATION
Quality-assured TB drugs
Prescriptions required
Accelerated registration
DS-TB TREATMENT
Daily fixed-dose combinations
WHO treatment guidance
Screening contacts and IPT
DR-TB TREATMENT
WHO DR-TB guidance
Essential Medicines List (EML)
Import waivers until registration
498DAYS
USE ON WEDNESDAY 26 OCTOBER
(The deadline is around World TB Day 2018)

9. DR-TB STAT Task Force
Formed in April 2015 in response to the “Call to Action” to accelerate access to new drugs for MDR-TB*
Officially adopted as a Global DR-TB Initiative task force in July 2015
Multiagency participation
Collects information from National TB Programs each month on the use of BDQ and DLM
Provides technical assistance and support for countries to overcome barriers to new drug introduction
Data current to 1 September 2016
See more at *

10. Bedaquiline progress
5234 patients enrolled as of 1 September 2016 (60% in South Africa, 20% in Russia)
4663 orders from GDF
As of 1 May 2016, BDQ has been registered with 12 regulatory authorities (Armenia, the European Union, India, Macau, Peru, Philippines, Russia, South Africa, South Korea, Taiwan, Turkmenistan, the United States, and Uzbekistan)
Dossiers have been submitted to an additional 17 countries
Dossiers have been submitted in Azerbaijan, Bangladesh, Belarus, China, Colombia, Hong Kong, Indonesia, Kazakhstan, Mexico, Moldova, New Zealand, Tanzania, Thailand, Uganda, Viet Nam. Of note, a dossier submitted in Kyrgyzstan was rejected on the basis that there was no phase III data. Additionally a joint application has been submitted for the following countries via a WHO pilot project for collaborative registration: Burundi, Cameroon, Ethiopia, Ghana, Kenya, Nigeria, Tanzania.

11. Delamanid progress 366 patients on DLM, all in MSF or PIH sites
1018 orders from GDF
DLM registered in Japan, South Korea, Hong Kong, the European Union, Turkey, and the Philippines; not registered in any MDR-TB high-burden countries
Dossiers have been submitted for registration in the Philippines, Indonesia, Turkey and Vietnam